 This Phase I randomized, double-blind, placebo-controlled, single-center study assessed the safety, tolerance, and pharmacokinetics of salvionolic acid B, sal-B, in healthy Chinese volunteers. The results indicated that sal-B was safe and well tolerated and administered at doses up to 300 mg in a single dose and 250 mg for five consecutive days. Additionally, the peak plasma concentration and area under the plasma concentration curve of sal-B progressively increased in a dose-dependent manner in the single ascending dose study groups. No serious adverse events occurred, and no volunteers withdrew from the trial. These findings suggest that sal-B may be a promising candidate for further investigation as a potential therapeutic agent for various diseases. This article was authored by Jun Lincheng, Jun Long, Jingjing Zhang, and others.